The mutational profile and infiltration pattern of murine MLH1-/- tumors: concurrences, disparities and cell line

Claudia Maletzki1, Franziska Beyrich1, Maja Hühns2

  • 1Molecular Oncology and Immunotherapy, Department of General Surgery, University of Rostock, 18057 Rostock, Germany.

Oncotarget
|July 23, 2016
PubMed

Insights

MLH1 knockout mice exhibit microsatellite instability and an active immune microenvironment, mirroring human DNA mismatch repair deficiency diseases like Lynch syndrome. These mice serve as valuable models for preclinical research into MMR-D related cancers.

Area of Science:

  • Oncology
  • Genetics
  • Immunology

Background:

  • DNA mismatch repair (MMR) deficiency underlies hereditary cancers, including Lynch syndrome.
  • Models for MMR-deficient (MMR-D) diseases are crucial for understanding carcinogenesis and developing therapies.
  • MLH1-/- knockout mice represent a potential model for both germline (Lynch syndrome) and biallelic MMR-D.

Purpose of the Study:

  • To characterize the MLH1-/- mouse model for MMR-D diseases.
  • To investigate the tumor-immune microenvironment and coding microsatellite mutations in MLH1-/- lymphomas and gastrointestinal tumors (GIT).

Main Methods:

  • Generation of MLH1-/- knockout mice.
  • Analysis of microsatellite instability (MSI) in coding and non-coding loci.
  • Immunofluorescence and mutational profiling of tumors.
  • Establishment and characterization of an MLH1-/- GIT cell line (A7450).

Main Results:

  • All MLH1-/- tumors displayed MSI in non-coding markers.
  • Mutational profiling identified instability in coding microsatellites, with Rfc3 and Rasal2 shared between lymphomas and GIT.
  • Tumors showed a mixed immune phenotype: immunosuppressive markers (CD11b, CD200R) alongside immune cells (CD3+ T cells) and checkpoints (PD-L1, CTLA-4).
  • The MLH1-/- A7450 cell line demonstrated stable growth, invasiveness, heterogeneous drug response, and identified additional MSI target genes.

Conclusions:

  • The MLH1-/- mouse model accurately reflects the molecular and immunological features of MMR-D diseases.
  • These mice are suitable preclinical models for Lynch syndrome and constitutional MMR-D.
  • The characterized cell line offers a platform for drug screening and mechanistic studies in MMR-D.